GPX4 and neoplasm: For the latter, although FDA-approved sorafenib and salazosulfapyridine have been shown to induce ferroptosis through this pathway, tumor cells can compensate for cysteine and GSH through the SLC7A11 protein, ASC transporter system, and thiol antioxidants, resulting in limited therapeutic effects.50 Conventional GPX4 inhibitors are prone to resistance because of the upregulation of SLC7A11 or FSP1.